FDA approves Novo Nordisk’s Wegovy to reduce cardiovascular risks
The U.S. Food and Drug Administration approved Novo Nordisk’s weight-loss drug Wegovy on Friday to reduce the risk of stroke and heart attack in overweight or obese adults without diabetes.
POPULAR POSTS
IEA warns ‘electricity era’ will come after fossil fuels peak
October 17, 2024
Easter Island fights global plastic waste vortex
October 17, 2024
Egypt opens more galleries at its antiquities museum
October 17, 2024
LIVE STREAM